Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Neuro Stents & Coils Technology and Market Forecast
4.
Outsourcing in Drug Discovery, 3rd Edition
5.
American Hospital Register
6.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
7.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Theranostics Report 2007-2012
Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it alot easier for you and your company.
This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process of drug development offers you and your company clear opportunities. This emerging field is generating interest from the healthcare industry and regulatory bodies, with the associated market expanding continually as the importance of theranostics is recognised.
Theranostic solutions are playing an increasingly important role in pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, theranostics is paving the way towards the long-held goal of personalised medicine, to the benefit of patients and payers. Theranostics has also received encouraging support from regulators such as the FDA. Pharmaceutical, diagnostics and biotechnological companies cannot afford to overlook this rapidly emerging field. So you should be sure you corner your percentage of the market immediately.
Theranostics 2007-2012 examines the market for theranostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses theranostics in the context of the wider diagnostics market. In addition to consultation with experts in industry, this research involved a detailed study of documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting and SWOT analyses. The result is a comprehensive market-based report with detailed analysis and informed opinion.
In particular, this report concentrates on the following essential aspects of the theranostics sector:
Technologies that drive the theranostics sector
Key industrial players in theranostics including partnerships in that field
Forecasts of the global theranostics market from 2007-2012, including forecasts of the molecular diagnostics market and principal market segments within theranostics
Drivers and opportunities in the theranostics sector
Restraints and threats in the theranostics sector
Assessments of relevant business models, technological solutions and associated issues
Coverage of future trends in the sector
Insight from a survey with experts from industry and academia
Why you should buy this report:
To receive a comprehensive analysis of the prospects for theranostics from 2007-2012
To discover predicted revenues, growth rates and other key metrics for theranostic solutions from 2006-2011
To receive the views of experts in the theranostics sector
To determine the forces that influence the market for theranostics: Competitive characteristics of the market, Drivers, Restraints, Strengths, weaknesses, opportunities and threats
To find out where theranostics is heading - both technologically and commercially
Visiongain predicts that all aspects of theranostics will exhibit strong growth in revenues from 2007-2012, with significant investments being made by far-sighted companies in the pharmaceutical, diagnostics and biotechnological sectors. Although still in its early stages of commercial development, theranostics will increasingly gain acceptance from stakeholders in healthcare. Successful participating companies will benefit as a result, gaining early market prominence from high-value products. But which areas of theranostics will that be? Find out today by ordering your executive copy of Theranostics 2007.
Publication Date: 31/01/07
Pages: 115
PDF Format
Table of Contents
Price
Single User Licence $2998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.